Compare ANIX & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIX | LRE |
|---|---|---|
| Founded | 1982 | 2001 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 17.9M |
| IPO Year | 2013 | 2022 |
| Metric | ANIX | LRE |
|---|---|---|
| Price | $2.77 | $1.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 332.0K | 9.3K |
| Earning Date | 05-27-2026 | 07-30-2015 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $1.00 |
| 52 Week High | $5.46 | $1.86 |
| Indicator | ANIX | LRE |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 26.21 |
| Support Level | $2.73 | N/A |
| Resistance Level | $3.09 | $1.33 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 16.36 | 33.87 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.